(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them - 2Pick Your #1 game to observe
- 3Ten Awesome Authentic Realities That Will Leave You Interested
- 4Opening Potential: Self-awareness and Long lasting Learning
- 5Cases of norovirus are on the rise just in time for the holiday season
- Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- Tablets: Upgrade Your Understanding Experience
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- April's full moon decides the date of Easter — here's how it works
- Israel's fractured opposition hands Netanyahu a full term
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- Muslim Brotherhood stole half a billion dollars in Gaza donations, Arab sources reveal
